Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia.

Oliver Andreas CornelyHelmut OstermannPhilipp KoehlerDaniel TeschnerEndrik LimburgWilliam G KramerSara H BarbatMargaret TawadrousMichael R Hodges

Published in: The Journal of antimicrobial chemotherapy (2023)

Fosmanogepix was safe and well tolerated in AML patients with neutropenia receiving remission induction chemotherapy. Safety and PK profiles were comparable to healthy volunteers.

Keyphrases

acute myeloid leukemia
chemotherapy induced
dendritic cells
bone marrow
squamous cell carcinoma
disease activity
rheumatoid arthritis
allogeneic hematopoietic stem cell transplantation